alnylam
The Medical Science Liaison will build and sustain scientific partnerships with key opinion leaders, investigators, and healthcare professionals across an assigned U.S. geography to advance understanding and treatment of transthyretin amyloidosis. The role focuses on delivering balanced scientific information, supporting clinical trial enrollment, and gathering medical insights to inform internal stakeholders, while traveling 60‑70% of the time.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
82% above the average for this role
Medical Science Liaison
Alnylam Pharmaceuticals
Medical Science Liaison (Miami/Ft.Lauderdale, FL)
Alnylam Pharmaceuticals
Medical Science Liaison (MSL)
Alumis
Medical Science Liaison (MSL) – Rare Diseases
AstraZeneca
Medical Science Liaison, Cell Therapy
Bristol Myers Squibb
Sr. Medical Science Liaison (MSL)
UCB